950 Winter Street
About Radius HealthRadius is a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases.
Radius is committed to the research and development of new therapeutics for the large and underserved osteoporosis market.
October 3, 2003
Founders: John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt and John T. Potts
CEO: Robert Ward
CMO (Medical): Lorraine Fitzpatrick
CFO: Nick Harvey
CSO (Scientific): Gary Hattersley
Please click here for Radius Health job opportunities.
Please click here for clinical trial information.
190 articles with Radius Health
Radius Health Announces Conference Call And Webcast On New Data For Investigational Drug RAD1901 To Be Presented At San Antonio Breast Cancer Symposium 2015
Radius Health Delays Osteoporosis Drug Application in the U.S. to Avoid Rush, Respect Staffers' Holidays
Radius Health Has Submitted A Marketing Authorization Application For The Investigational Drug Abaloparatide-SC For The Treatment Of Postmenopausal Osteoporosis In Europe
Radius Health To Present Promising Single-Agent Data For Investigational Oral Drug RAD1901 At 2015 American Association For Cancer Research – National Cancer Institute – European Organization For Research And Treatment Of Cancer (AACR-NCI-EORTC) Internati
Radius Health Release: Investigational Drug Abaloparatide Reduces The Incidence Of Fractures In Postmenopausal Women With Osteoporosis
Radius Health Presents Positive Phase 3 Top-Line Data For Investigational Osteoporosis Therapy Abaloparatide At The American Society For Bone And Mineral Research 2015 Annual Meeting
Radius Health Announces Webcast On Investigational Drug RAD1901, Upcoming Presentations And Investor Day In New York City On November 17th, 2015
Radius Health To Announce Second Quarter 2015 Financial Results, Host Conference Call And Live Webcast On August 6, 2015
Radius Health Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares